Cart 0

MarketsandMarkets

Regenerative Medicine Market- Forecast to 2021

$5,650.00

Report Published By: MarketsandMarkets
Publication Date : Feb-17
No. Of Pages: 140

“Regenerative Medicine Market by Therapy (Cell Therapy, Tissue Engineering, Immunotherapy, Gene Therapy), By Product (Cell-Based, Acellular), By Applications (Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology)-Forecast To 2021”
The global Regenerative medicine market is expected to reach USD 38.70 billion by 2021 from USD 13.41 billion in 2016 at a CAGR of 23.6% from 2016 to 2021
The major factor driving the growth of regenerative medicine market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population.
The global Regenerative medicine market is segmented based on type, therapy, application, and regions. The cell-based products segment is expected to register to have largest market share in the Regenerative medicine market, by type, during the forecast period. The high growth in this segment is attributed to the increasing awareness about stem cell therapy, growing funding for new stem cell lines, and development of advanced genomic methods.
On the basis of therapy, the cell therapy procedure is expected to account for the largest share of the market in 2016. Increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies will drive the growth of this market.
On the basis of applications, the segments are orthopedic & musculoskeletal disorders, dermatology, cardiology, diabetes, central nervous system diseases, and other applications. Oncology is the fastest growing application market. Increasing cancer incidence, rich product pipeline and increasing demand for cancer treatments fuelling the growth of the market.
Geographically, the Regenerative medicine market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by rapidly increasing aging population and increase in chronic diseases are the major drivers for developed economies like the U.S.
The key players in the cell-based products segment are Organogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.). The key players in the acellular products segment are Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), and C.R. Bard (U.S.).

Research Coverage:
The report analyses the Regenerative medicine market by type, therapy, application and regions. Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the Regenerative medicine market.
Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the Regenerative medicine market.
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the Regenerative medicine market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the Regenerative medicine market
• Market Development: Comprehensive information about emerging markets. This report analyses the market for various Regenerative medicine market products across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Regenerative medicine market.

TABLE OF CONTENTS

1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 MARKET SCOPE 12
1.3.1 MARKETS COVERED 13
1.3.2 YEARS CONSIDERED FOR THE STUDY 13
1.4 CURRENCY 13
1.5 LIMITATIONS 14
1.6 STAKEHOLDERS 14
2 RESEARCH METHODOLOGY 15
2.1 MARKET SIZE ESTIMATION 16
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 19
2.3 MARKET SHARE ESTIMATION 20
2.3.1 KEY DATA FROM SECONDARY SOURCES 20
2.3.2 KEY DATA FROM PRIMARY SOURCES 21
2.3.3 ASSUMPTIONS FOR THE STUDY 21
3 EXECUTIVE SUMMARY 22
4 PREMIUM INSIGHTS 25
4.1 REGENERATIVE MEDICINE: MARKET OVERVIEW 25
4.2 GEOGRAPHIC ANALYSIS: REGENERATIVE MEDICINE MARKET, BY THERAPY, 2016 26
4.3 GEOGRAPHICAL SNAPSHOT OF THE REGENERATIVE MEDICINE MARKET 27
5 MARKET OVERVIEW 28
5.1 INTRODUCTION 29
5.2 MARKET DYNAMICS 29
5.3 DRIVERS 30
5.3.1 GOVERNMENT & PRIVATE FUNDING TO SUPPORT THE DEVELOPMENT OF REGENERATIVE MEDICINE 30
5.3.2 RISING PREVALENCE OF CHRONIC DISEASES AND GENETIC DISORDERS 30
5.3.3 INCREASE IN GLOBAL HEALTHCARE EXPENDITURE 31
5.3.4 RAPID GROWTH IN THE AGING POPULATION 31
5.3.5 INCREASE IN CORPORATE PARTNERSHIPS TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF REGENERATIVE MEDICINE 32
?
5.4 RESTRAINTS 33
5.4.1 ETHICAL CONCERNS WITH THE USE OF EMBRYONIC STEM CELL FOR R&D 33
5.4.2 LACK OF CLEAR REGULATORY GUIDELINES 33
5.5 OPPORTUNITIES 34
5.5.1 RISING DEMAND FOR ORGAN TRANSPLANTATION 34
5.5.2 STRONG PRODUCT PIPELINE 34
6 GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT 36
6.1 INTRODUCTION 37
6.2 CELL-BASED PRODUCTS 39
6.2.1 ALLOGENEIC PRODUCTS 41
6.2.2 AUTOLOGOUS PRODUCTS 42
6.3 ACELLULAR PRODUCTS 43
7 GLOBAL REGENERATIVE MEDICINE MARKET, BY THERAPY 44
7.1 INTRODUCTION 45
7.2 CELL THERAPY 46
7.3 TISSUE ENGINEERING 48
7.4 IMMUNOTHERAPY 49
7.5 GENE THERAPY 50
8 REGENERATIVE MEDICINE MARKET, BY APPLICATION 52
8.1 INTRODUCTION 53
8.2 ORTHOPEDIC & MUSCULOSKELETAL DISORDERS 55
8.3 DERMATOLOGY 56
8.4 CARDIOLOGY 57
8.5 CENTRAL NERVOUS SYSTEM DISEASES 57
8.6 ONCOLOGY 59
8.7 DIABETES 60
8.8 OTHER APPLICATIONS 61
9 GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION 63
9.1 INTRODUCTION 64
9.2 NORTH AMERICA 65
9.2.1 U.S. 69
9.2.2 CANADA 72
?
9.3 EUROPE 75
9.3.1 GERMANY 79
9.3.2 U.K. 82
9.3.3 FRANCE 84
9.3.4 ITALY 86
9.3.5 SPAIN 88
9.3.6 REST OF EUROPE (ROE) 91
9.4 ASIA-PACIFIC 93
9.5 REST OF THE WORLD (ROW) 98
10 COMPETITIVE LANDSCAPE 102
10.1 OVERVIEW 102
10.2 MARKET RANKING 103
10.3 COMPETITIVE SITUATION AND TRENDS 105
10.3.1 ACQUISITIONS 106
10.3.2 PARTNERSHIPS 107
10.3.3 REGULATORY APPROVALS 108
10.3.4 NEW PRODUCT DEVELOPMENTS 109
10.3.5 OTHERS 110
11 COMPANY PROFILES 111
(Overview, Financial*, Products & Services, Strategy, and Developments)
11.1 ACELITY L.P. INC. (KCI LICENSING) 111
11.2 NUVASIVE, INC. 113
11.3 VERICEL CORPORATION 115
11.4 OSIRIS THERAPEUTICS, INC. 117
11.5 INTEGRA LIFESCIENCES CORPORATION 119
11.6 STRYKER CORPORATION 122
11.7 MEDTRONIC PLC 124
11.8 COOK BIOTECH INCORPORATED 126
11.9 ORGANOGENESIS INC. 128
11.10 JAPAN TISSUE ENGINEERING CO., LTD. (SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION) 129
*Details might not be captured in case of unlisted companies.
12 APPENDIX 130
12.1 INSIGHTS FROM INDUSTRY EXPERTS 130
12.2 DISCUSSION GUIDE 131
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 133
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 135
12.5 AVAILABLE CUSTOMIZATIONS 135
12.6 RELATED REPORTS 136
12.7 AUTHOR DETAILS 137
LIST OF TABLES

TABLE 1 KEY CORPORATE PARTNERSHIPS, 2016 32
TABLE 2 GENE THERAPY PRODUCTS IN CLINICAL TRIALS, 2016 34
TABLE 3 CELL AND GENE THERAPY CLINICAL PRODUCT PIPELINE, 2016 34
TABLE 4 GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 38
TABLE 5 CELL-BASED PRODUCTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 39
TABLE 6 CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 40
TABLE 7 ALLOGENEIC PRODUCTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 41
TABLE 8 AUTOLOGOUS PRODUCTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 42
TABLE 9 ACELLULAR PRODUCTS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 43
TABLE 10 GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 46
TABLE 11 STEM CELL THERAPIES IN PHASE III DEVELOPMENT, 2016 47
TABLE 12 CELL THERAPY MARKET SIZE, BY REGION, 2014-2021 (USD BILLION) 48
TABLE 13 TISSUE ENGINEERING MARKET SIZE, BY REGION, 2014-2021 (USD BILLION) 49
TABLE 14 IMMUNOTHERAPY MARKET SIZE, BY REGION, 2014-2021 (USD BILLION) 50
TABLE 15 GENE THERAPIES IN CLINICAL TRIALS, 2016 51
TABLE 16 GENE THERAPY MARKET SIZE, BY REGION, 2014-2021 (USD BILLION) 51
TABLE 17 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE, BY THERAPEUTIC CATEGORY (2016) 53
TABLE 18 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE, BY PHASE (2016) 54
TABLE 19 REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 54
TABLE 20 ORTHOPEDIC & MUSCULOSKELETAL DISORDERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 55
TABLE 21 DERMATOLOGY MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 56
TABLE 22 CARDIOLOGY MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 57
TABLE 23 CENTRAL NERVOUS SYSTEM DISEASES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 58
TABLE 24 CANCER PATIENTS (GLOBAL), BY CANCER TYPE, 2015–2035 59
TABLE 25 ONCOLOGY MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 60
TABLE 26 DIABETES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 61
TABLE 27 OTHER APPLICATIONS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 62
TABLE 28 GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 64
TABLE 29 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 66
TABLE 30 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 67
TABLE 31 NORTH AMERICA: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 68
TABLE 32 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION) 68
TABLE 33 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 69
TABLE 34 U.S.: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 70
TABLE 35 U.S.: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 70
TABLE 36 U.S.: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 71
TABLE 37 U.S.: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 71
TABLE 38 CANADA: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 72
TABLE 39 CANADA: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 73
TABLE 40 CANADA: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 73
TABLE 41 CANADA: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 74
TABLE 42 EUROPE: REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 76
TABLE 43 EUROPE: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 77
TABLE 44 EUROPE: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 77
TABLE 45 EUROPE: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 78
TABLE 46 EUROPE: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 79
TABLE 47 GERMANY: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 80
TABLE 48 GERMANY: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 81
TABLE 49 GERMANY: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 81
TABLE 50 GERMANY: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 82
TABLE 51 U.K.: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 82
TABLE 52 U.K.: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 83
TABLE 53 U.K.: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 83
TABLE 54 U.K.: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 84
TABLE 55 FRANCE: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 84
TABLE 56 FRANCE: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 85
TABLE 57 FRANCE: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 85
TABLE 58 FRANCE: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 86
TABLE 59 ITALY: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 87
TABLE 60 ITALY: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 87
TABLE 61 ITALY: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 87
TABLE 62 ITALY: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 88
TABLE 63 SPAIN: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 89
TABLE 64 SPAIN: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 89
TABLE 65 SPAIN: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 90
TABLE 66 SPAIN: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 90
TABLE 67 ROE: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 91
TABLE 68 ROE: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 91
TABLE 69 ROE: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 92
TABLE 70 ROE: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 92
TABLE 71 ASIA-PACIFIC: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 95
TABLE 72 ASIA: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 96
TABLE 73 ASIA-PACIFIC: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 96
TABLE 74 ASIA-PACIFIC: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2013–2021 (USD BILLION) 97
TABLE 75 ROW: REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 99
TABLE 76 ROW: CELL-BASED PRODUCTS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 99
TABLE 77 ROW: REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 100
TABLE 78 ROW: REGENERATIVE MEDICINE MARKET SIZE, BY THERAPY,
2014–2021 (USD BILLION) 101
TABLE 79 RANKING OF MAJOR PLAYERS IN THE GLOBAL CELL-BASED REGENERATIVE MEDICINE MARKET (2015) 103
TABLE 80 RANKING OF MAJOR PLAYERS IN THE GLOBAL ACELLULAR REGENERATIVE MEDICINE MARKET (2015) 103
TABLE 81 KEY PRODUCTS IN THE CELL-BASED REGENERATIVE MEDICINE MARKET (2015) 103
TABLE 82 KEY PRODUCTS IN THE ACELLULAR REGENERATIVE MEDICINE MARKET (2015) 104
TABLE 83 ACQUISITIONS, 2014–2017 106
TABLE 84 PARTNERSHIPS, 2014–2016 107
TABLE 85 REGULATORY APPROVALS, 2014–2016 108
TABLE 86 NEW PRODUCT DEVELOPMENTS, 2013–2016 109
TABLE 87 OTHERS, 2014–2016 110

* indicates required information

* indicates required information


Share this Product


More from this collection